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Introduction: BCG vaccination has been associated with beneficial non-specific effects on child health.
Some immunological studies have reported heterologous effects of vaccines on antibody responses to
heterologous vaccines. Within a randomised clinical trial of Bacille Calmette-Guérin (BCG) vaccination
at birth, The Danish Calmette Study, we investigated the effect of BCG at birth on the antibody response
to the three routine vaccines against DiTeKiPol/Act-Hib and Prevenar 13 in a subgroup of participants.
Methods: Within 7 days after birth, children were randomised 1:1 to BCG vaccination or to the control
group (no intervention). After three routine vaccinations given at age 3, 5 and 12 months, antibodies
against DiTeKiPol/Act-Hib and Prevenar 13 (Streptococcus pneumoniae serotype type 4, 6B, 9V, 14, 18C,
19F and 23F) were measured 4 weeks after the third vaccine dose.
Results: Among the 300 included children (178 BCG; 122 controls), almost all children (>96%) had anti-
body responses above the protective levels. Overall BCG vaccination at birth did not affect the antibody
level. When stratifying by ‘age at randomisation’ we found a possible inducing effect of BCG on antibodies
against B. pertussis and all pneumococcal serotypes, when BCG was given after the first day of life. Girls
had significantly higher antibody levels for Haemophilus influenza type b and pneumococcus than boys.
Conclusions and relevance: Three routine vaccinations with DiTeKiPol/Act-Hib and Prevenar 13 induced
sero-protective levels in almost all children. No overall effect of neonatal BCG vaccination was observed.
 2017 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Bacille Calmette-Guérin (BCG) is among the most widely used
vaccines worldwide. Since it was introduced in the 1920s, BCG
has been the only vaccine used for the prevention of tuberculosis
(TB) [1,2]. The most significant protection is seen against the more
severe forms of TB such as milliary TB and TB meningitis [3,4].
BCG may protect not only against TB, but also against other
potentially fatal infections [5–7]. In a recent review of the evidence
for non-specific effects (NSE) of vaccines, BCG was found to reduce
the overall mortality much more than can be explained solely by
the specific protection against TB [8]. Other studies have recently
investigated the NSEs of BCG on diabetes and eczema, and sup-
ported that BCG has broader effects [9–12]. As a consequence,
WHO recommends further research into NSEs of BCG and other
vaccines [13].
Several immunological studies have focused on the possible
underlying biological mechanisms of NSEs of vaccines, including
heterologous T-cell immunity and trained innate immunity [14].
BCG vaccination has been found to alter in vitro cytokine responses
to non-related antigens and mitogens in both low- and high-
income countries [15–17]. This has been linked to epigenetic
reprogramming of monocytes, which also translated into increased
protection against a heterologous infectious challenge in mice [18].
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An Australian study of the effect of BCG on antibody response
from routine vaccines given during childhood found that BCG
was associated with significantly higher response of several sub-
classes of the pneumococcus conjugate vaccine (PCV) [19].
From 2012 to 2015 The Danish Calmette Study investigated the
effect of BCG vaccination at birth on childhood morbidity; the
study was sized to examine the risk of all cause hospitalisation
and atopic dermatitis as the main outcomes. In the present sub-
study we investigated the effect of BCG on antibody responses to
routine vaccines given during the first year of life.
2. Methods
2.1. Study design and population
The Danish Calmette Study is a randomised clinical trial inves-
tigating the effect of neonatal BCG vaccination on childhood mor-
bidity at three study sites. From October 2012 to November 2013,
4262 children were randomised to receive either BCG or no BCG;
no placebo was used. All children were randomised within the first
7 days of life. Children were followed by telephone interviews and
clinical examinations at the recruitment sites at 3 and 13 months
of age. The study is described in detail elswhere [20].
The present antibody study was conducted at ‘‘Hvidovre
Hospital” from April 2014 to December 2014. It was based on blood
samples from two subpopulations. The first subpopulation (cohort
I) consisted of infants born from May to November 2013 enrolled
in a sub-study on cytokine responses in whole blood stimulated
at age 4 days, 3 and 13 months (Nissen et al. 2016). The 13-
months blood samples were analysed for antibody levels for the
present study. To achieve sufficient power, a second subpopulation
(cohort II) of infants seen for 13-months follow-up in the period
from April to December 2014, were enrolled at age 13 months.
At recruitment (cohort I) or at the 13-months telephone inter-
view (cohort II), families were asked for consent to participate in
the present study. Blood samples were collected at the 13-month
clinical examination at the hospital; this examination was
scheduled 4 weeks after the third dose of DiTeKiPol/Act-Hib
(Statens Serum Institut) and Prevenar 13 (Pfizer Limited)
(Streptococcus pneumoniae serotype type 1, 3, 4, 5, 6A, 6B, 7F, 9V,
14, 18C, 19A, 19F and 23F).
2.2. Blood collection
Blood was collected in 4 mL Z Serum Separator, VACUETTE
TUBE, Greinor Bio-One. Serum was aliquoted into Thermo Scien-
tific 1 mL cryotubes and stored at 80 C until analysis.
2.3. Intervention
The BCG Danish strain 1331 (Statens Serum Institut) was used
in The Danish Calmette Study. A recommended dose of 0.05 mL
of the vaccine suspension was applied intradermally in the left
upper arm.
2.4. Routine vaccinations
According to the Danish vaccination programme children are
vaccinated at 3, 5, and 12 months with DiTeKiPol/Act-Hib
(Corynebacterium diphtheria toxoid (DT), Clostridium tetanus toxoid
(TT), Bordetella pertussis toxoid (PT), Polio virus type 1–3, Hae-
mophilus influenzae type b polysaccharide (Hib)), and Prevenar 13.
During some of the recruitment period, DiTeKiPol/Act-Hib was
not available due to production problems and was temporarily
replaced by 1–3 doses of Infanrixhexa (GlaxoSmithKline). The main
differences between DiTeKiPol/Act-Hib and Infanrixhexa are
HBsAg, the B. pertussis component and the aluminium content
(Supplementary Table 1).
2.5. Antibody assay
IgG antibodies directed against B. pertussis, C. diphtheria,
C. tetani, H. influenzae type b and S. pneumoniae were measured
using a fluorescent bead-based multiplex immuno-assay (Luminex
xMAP technology). All plates (Millipore, Amsterdam, The Nether-
lands) contained a reference, controls and blanks. Analyses were
performed with a Bio-Plex 200 in combination with Bio-Plex
manager software (Bio-Rad Laboratories, Hercules, CA, USA).
For measurement of antibodies against B. pertussis, diphtheria
and tetanus, the samples were diluted 1/200 and 1/4000 in
phosphate-buffered saline (Tritium, Eindhoven, The Netherlands)
containing 0.1% Tween-20 (Merck Millipore, Billerica, MA) and 3%
bovine serum albumin (Sigma-Aldrich, St. Louis, MO). Serum val-
ues for B. pertussis were assigned in IU/ml as the used reference
was calibrated against the U.S. Reference Pertussis Anti-serum
Human lot 3 (Ptx and FHA) and lot 4 (Prn) (CBER/FDA). For diph-
theria and tetanus, serum values were expressed in IU/ml as the
reference serum was calibrated against the international standards
(NIBSC code Di-03 and NIBSC code TE-03) [21–24].
For measurement of antibodies against H. influenzae type b, the
samples were diluted 1/100 in 50% antibody depleted human
serum (ADHS, Valley Biomedical). Serum values were expressed
in mg/ml as the reference serum was calibrated against the interna-
tional reference serum Lot1983 (CBER/FDA) [24].
For measurement of antibodies against 7 serotypes S. pneumo-
niae (4, 6B, 9V, 14, 18C, 19F and 23F), the samples were diluted
1/1000 in 5% ADHS containing 15 mg/ml multi CWPS (Statens
Serum Institut). Serum values were expressed in mg/ml as the
reference serum was calibrated against the international reference
serum lot 89S (FDA) [25].
2.6. Statistical analysis
To detect a difference of 10% in antibody levels, 300 infants
(150 from each group) needed to be included (a: 0.05, b: 0.10)[26].
Before unblinding, a statistical analysis plan was deposit with
the Danish Calmette Study Data Safety and Monitoring Bard. In
accordance with the statistical analysis plan, in each randomisa-
tion group we report the proportion of children with a non-
protective level of antibodies according to standard cut-off values
for each vaccine. Antibody levels are presented as geometric mean
concentrations (GMC). The effect of BCG vaccination is presented
as a geometric mean ratio (GMR) with 95% confidence interval
(CI) obtained as the anti-logged coefficient from a linear regression
with log-concentrations as outcome and randomisation group as
co-variate. A 5%-significance level is used. We had pre-specified
to test the following factors for effect modification: maternal
BCG, sex, ‘age at randomisation’ (which was pre-specified as
0–1 day versus 2–7 days, as most children were enrolled during
the first days of life and there was limited power to analyse the
effect on subsequent days), age at bleeding, time from third
pentavalent vaccine to bleeding, and doses of Infanrixhexa. All sta-
tistical analyses were performed using STATA 13.1 (Statacorp LP,
College Station, TX, USA).
2.7. Ethics
The trial was approved by the Committee of Biomedical
Research Ethics (J.no. H-3-2010-087), the Danish Data Protection
Board (J.no. 2009-41-4141), and the Danish Medicines Agency
(J.no. 2612-4356. EudraCT 2010-021979-85. Protocol 2009-323).
The trial was registered at www.ClinicalTrials.gov (NCT01694108)
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and monitored by the Good Clinical Practice Unit and an indepen-
dent Data Safety Monitoring Board.
3. Results
Of the 304 children recruited for the study, two controls were
excluded because they sought BCG vaccination outside the study
and two (1 BCG; 1 control) were excluded from the analysis
because they were bled before their third pentavalent vaccine.
The remaining 300 children all received three doses of DiTeKiPol/
Act-Hib or Infanrixhexa and three doses of Prevenar 13 before
bleeding. Included in the analysis 142 of the children (75 BCG;
67 controls) were recruited as part of cohort I; 158 of the children
(103 BCG; 55 controls) belonged to cohort II. Thus, 178 BCG
vaccinated children and 122 control children were included in
the final analysis.
For most of the clinical parameters, the two groups had similar
background characteristics (Table 1). However, in the BCG group
22% of the mothers were BCG vaccinated compared to 12% in the
control group (p-value 0.04); this was due to a difference in cohort
II (Supplementary Table 2). Also 25% in the BCG group had 1–3
doses of Infanrixhexa compared to 42% in the control group
(p-value 0.002), this was due to a difference in cohort I
(Supplementary Table 2).
3.1. Vaccination programme
Parents were asked at the 13-months interview which vaccines
their child had received. Due to a temporary shift from DiTeKiPol/
Act-Hib to Infanrixhexa in the Danish vaccination programme for
some children one to three doses of the intended DiTeKiPol/
Act-Hib were replaced with Infanrixhexa. The change of vaccines
caused no delay in the timing of vaccination at any of the three
time points (Table 1). According to protocol we only examined
antibody levels against diseases present in both vaccines. When
analysing the agreement between parent-reported information
on doses of Infanrixhexa (1–3 or none), and antibodies against
components present only in this vaccine, we found that 26%
(54/205) children registered as having received no Infanrixhexa,
had in fact antibodies against Pertactin (Prn), indicating that they
received at least one dose of Infanrixhexa. Classifying these chil-
dren as having received 1–3 doses of Infanrixhexa did not change
the estimates where this co-variable was included in the analysis.
3.2. The effect of BCG on achieving protective antibody levels
The routine vaccination was effective; four weeks post-
vaccination almost all children had antibody levels above the pro-
tection limit. BCG did not affect the probability of having titres
above the protective level (Table 2).
3.3. The effect of BCG on antibody levels
There was no difference between BCG and controls with respect
to antibody levels, neither overall, nor when adjusted for the back-
ground factors (maternal BCG and Infanrixhexa), which varied
between the groups (Table 3, Fig. 1).
3.4. Effect modification by ‘age at randomisation’
BCG was associated with higher GMC of anti-PT and anti-Hib
IgG among children randomised on day 2–7, and lower GMC
among children randomised on day 0–1. The interaction between
BCG and age of randomisation reached statistical significance for
anti-PT IgG with a GMR of 0.91 (95% CI 0.70–1.18) in the group
randomised on day 0–1 compared with a GMR of 1.47 (95% CI
1.08–2.00) in the group randomised on day 2–7 (p-value = 0.02
for interaction between BCG and ‘age at randomisation’). Though
not significant in the interaction test there was a similar tendency
for anti-Hib IgG; the group randomised on day 0–1 had a GMR of
0.64 (95% CI 0.40–1.05) compared to a GMR of 1.2 (95% CI
0.68–2.12) in the group randomised on day 2–7 (p-value = 0.10
for interaction between BCG and ‘age at randomisation’) (Fig. 2).
Also, the GMC of pneumococcal IgG serotypes tended to be
higher in the BCG group for children randomised on day 2–7
whereas the GMC was lower in the BCG group for children
Table 1
Background characteristics of study population.
BCG N = 178
n (%)
Control N = 122
n (%)
p-value
Age in days at randomisation (median (IQR)) 1 (1–3) 1 (1–3) 0.54
Age group at randomisation
0–1 days 103 (58) 71 (58) 0.95
2–7 days 75 (42) 51 (42)
Sex (male) 107 (60) 66 (54) 0.30
Gestational age (GA) in weeks (median (IQR)) 40.3 (39.2–40.9) 40.6 (39.4–41.1) 0.34
Weight in kg (median (IQR)) 3.51 (3.26–3.84) 3.55 (3.19–3.88) 0.80
Caesarean section 31 (17) 26 (21) 0.53
Maternal BCGa 38 (22) 15 (12) 0.04
At least one parent of non-Danish ethnicity 30 (17) 19 (16) 0. 47
Maternal smoking during pregnancy 15 (8) 9 (7) 0.74
Level of maternal education
Basic schooling and non-theoretical education 31 (18) 29 (24) 0.29
Theoretical education incl. BA level 87 (49) 50 (41)
Master level or more 59 (33) 42 (35)
Siblings 71 (40) 40 (33) 0.21
Atopic predisposition 118 (66) 72 (59) 0.20
Age in days at routine vaccination (median (IQR))
- 3 months 93 (91–99) 92 (92–99) 0.97
- 5 months 154 (153–161) 155 (153–161) 0.89
- 12 months 372 (366–380) 369 (362–378) 0.27
Time in days from third pentavalent vaccine to bleeding (median (IQR)) 34 (30–40) 35 (30–41) 0.96
Infanrixhexa 1–3 doses 44 (25) 51 (42) 0.002
a Two mothers with unknown BCG status excluded from the analysis.
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randomised on day 0–1. This interaction was statistically
significant for serotype 9v (p-value = 0.005); serotype 18c (p-value =
0.02); and serotype 19f (p-value = 0.007) (Fig. 3).
3.5. Effect modification by sex and maternal BCG
Girls responded with significantly higher antibody levels than
boys for Haemophilus influenza type b and pneumococcus (Supple-
mentary Table 3). Most infants achieved protective levels, and
there was a tendency towards more girls than boys had antibody
levels above the protection limit. (Supplementary Table 4). No
difference in the effect of BCG by sex (data not shown) or effect
modification by maternal BCG status on antibody responses
(Supplementary Table 5) was observed.
Analyses by age at bleeding, time from 12-month vaccine to
bleeding and doses of Infanrixhexa did not show any modifying
effect of BCG (data not shown).
4. Discussion
This is the first study in a high-income setting with a ran-
domised design to investigate the effect of BCG vaccination at birth
on antibody response from pentavalent vaccines given during the
first year of life. Almost all children (>96%) had antibody responses
above the protective levels, and we were not able to detect any
additional improvement by administering BCG vaccine at birth.
Stratifying for ‘age at randomisation’, we found a possible enhanc-
ing effect of BCG vaccination on antibody levels against B. pertussis
and pneumococcal serotypes when BCG vaccine was administered
after the first days of life. Girls had higher antibody responses
towards Haemophilus influenza type b and pneumococcus than
boys.
4.1. Strengths and limitations
The study is a randomised design with allocation to BCG or no
BCG, and the study was conducted in a country with a high adher-
ence to the national vaccination programme.
The two groups were comparable with regard to age at
12-month vaccination and time from vaccination to bleeding.
Unfortunately, there was an uneven distribution of children in
the BCG group (N = 178) and the control group (N = 122). Some
children were included from another sub-study (Nissen 2016) in
which parents consented before the randomisation (75 BCG; 67
controls); the rest of the children were included at the 13-month
telephone interview (103 BCG; 55 controls). This unbalanced
recruitment of participants of the antibody cohort was a result of
a decreased willingness of participants randomised to the control
group to participate, as we invited children by random without
knowledge about their randomisation status. Thus, parents of
BCG-vaccinated children were more prone to participate in our
study, including bleeding of the child, when contacted at the
13-month telephone interview [27]. To show a significant differ-
ence of 10% between the BCG vaccinated and controls we needed
150 children in each group. The uneven distribution, in addition
to the higher standard deviations in our data compared to the data
Table 2
Proportion of children with an antibody responses above the limit of protection – comparing BCG vaccinated and controls.
Protection limit All N = 300
% (n)
BCG N = 178
% (n)
Control N = 122
% (n)
p-valuea
Pertussis 20 IU/ml 99 (297) 99.4 (177) 98.4 (120) 0.36
Diphtheria 0.1 IU/mL 99.7 (299) 99.4 (177) 100 (122) 0.40
Tetanus 0.1 IU/mL 100 (300) 100 (178) 100 (122) 1
Haemophilus influenza type b 0.15 mg/mL 97 (291) 97.2 (173) 96.7 (118) 0.82
Pneumococcus
Serotype 4 0.35 mg/mL 99 (297) 98.9 (176) 99.2 (121) 0.79
Serotype 6b 0.35 mg/mL 98 (294) 98.9 (176) 96.7 (118) 0.19
Serotype 9 v 0.35 mg/mL 99 (297) 98.9 (176) 99.2 (121) 0.79
Serotype 14 0.35 mg/mL 99.7 (299) 100 (178) 99.2 (121) 0.23
Serotype 18c 0.35 mg/mL 99.3 (298) 99.4 (177) 99.2 (121) 0.79
Serotype 19f 0.35 mg/mL 99.7 (299) 100 (178) 99.2 (121) 0.23
Serotype 23f 0.35 mg/mL 98.3 (295) 98.3 (175) 98.4 (120) 0.98
IU: International Units.
a Chi2 test for differences between groups.
Table 3
Geometric mean concentration (GMC) and geometric mean ratio (GMR) of IgG comparing BCG vaccinated and controls.
BCG (N = 178) Control (N = 122) Unadjusted (N = 300) p-value Adjusteda (N = 300) p-value
GMC 95% CI GMC 95% CI GMR (95% CI) GMR (95% CI)
Pertussis 180 (158–205) 162 (139–189) 1.11 (0.91–1.36) 0.31 1.13 (0.92–1.39) 0.25
Diphtheria 1.66 (1.47–1.86) 1.71 (1.49–1.97) 0.97 (0.81–1.16) 0.72 0.98 (0.81–1.19) 0.86
Tetanus 1.87 (1.65–2.11) 2.02 (1.74–2.35) 0.92 (0.76–1.12) 0.43 0.95 (0.78–1.16) 0.64
Haemophilus influenza type b 6.58 (5.20–8.34) 7.88 (5.92–10.5) 0.84 (0.58–1.21) 0.34 0.78 (0.53–1.13) 0.19
Pneumococcus
Serotype 4 9.21 (8.02–10.6) 9.51 (8.05–11.2) 0.97 (0.78–1.20) 0.77 0.96 (0.77–1.20) 0.72
Serotype 6b 10.3 (8.65–12.3) 9.58 (7.73–11.9) 1.08 (0.82–1.43) 0.59 1.07 (0.81–1.43) 0.62
Serotype 9v 9.46 (8.28–10.8) 9.70 (8.25–11.4) 0.98 (0.79–1.20) 0.82 0.99 (0.80–1.23) 0.93
Serotype 14 11.2 (9.79–12.8) 10.4 (8.81–12.2) 1.08 (0.88–1.33) 0.47 1.12 (0.91–1.39) 0.29
Serotype 18c 10.9 (9.26–12.8) 9.14 (7.30–11.5) 1.15 (0.93–1.42) 0.20 1.16 (0.93–1.44) 0.19
Serotype 19f 53.1 (45.2–62.4) 53.3 (42.7–66.6) 1.00 (0.80–1.24) 0.99 0.99 (0.79–1.23) 0.90
Serotype 23f 11.8 (9.77–14.2) 10.8 (8.38–14.0) 1.05 (0.82–1.35) 0.71 1.06 (0.82–1.37) 0.67
a Adjusted for maternal BCG and Infanrixhexa.
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the sample size was based on, poses a risk for type-2 errors, but the
difference seems unlikely to result in systematic bias.
Despite the fact that almost all children adhered to the Danish
Vaccination Programme, the children received different combina-
tions of childhood vaccines. This was due to a sudden temporary
shift insupply from Statens Serum Institut leading to replacement
of DiTeKiPol/Act-Hib with Infanrixhexa, which was unfortunate
for this study, but impossible to predict or influence. We are con-
fident that the parental reporting of number of childhood vaccines
is accurate, but parental distinction between DiTeKiPol/Act-Hib
vaccine and Infanrixhexa may be uncertain, as witnessed by the
high proportion of children who were reported to have received
the ‘‘usual” DiTeKiPol/Act-Hib vaccine, but who had nonetheless
antibodies against the Prn component present in Infanrixhexa.
However, it made no difference to the conclusions whether we
classified children according to parental recall or by antibody
responses to Prn, and importantly, the change in vaccination type
was not associated with any delays in the timing of vaccination,
which could have confounded the analysis.
0
5
10
15
40
50
60
70 E
G
eo
m
et
ric
 M
ea
n 
C
on
ce
nt
ra
tio
n
of
 a
nt
i-P
nP
s 
Ig
G
 ( 
 g
/m
L)
BCG
Control
0
50
100
150
200
250 A
G
eo
m
et
ric
 M
ea
n 
C
on
ce
nt
ra
tio
n
of
 a
nt
i-P
T 
Ig
G
 (I
U
/m
L)
0.0
0.5
1.0
1.5
2.0
2.5 B
G
eo
m
et
ric
 M
ea
n 
C
on
ce
nt
ra
tio
n
of
 a
nt
i-D
T 
Ig
G
 (I
U
/m
L)
0.0
0.5
1.0
1.5
2.0
2.5 C
G
eo
m
et
ric
 M
ea
n 
C
on
ce
nt
ra
tio
n
of
 a
nt
i-T
T 
Ig
G
 (I
U
/m
L)
4 6b 9v 14 18c 19f 23f
BCG Control BCG Control
BCG Control BCG Control
0
5
10
15 D
G
eo
m
et
ric
 M
ea
n 
C
on
ce
nt
ra
tio
n
of
 a
nt
i-H
ib
 Ig
G
 ( 
 g
/m
L)
Fig. 1. Geometric mean concentrations (GMCs) of antibodies against A: anti-pertussis toxin (anti-PT), B: anti-diphtheria toxin (anti-DT), C: anti-tetanus toxin (anti-TT), D:
anti-haemophilus influenzae type b, E: pneumococcal capsular polysaccharide antigens (anti-Pn Ps IgG) for each pneumococcal serotype. Error bars depict 95% CI.
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Fig. 2. Geometric mean ratios (GMRs) of the effect of BCG on antibodies against:
anti-PT IgG, anti-DT IgG, anti-TT IgG, anti-Hib IgG. Dots display all children, squares
display children randomised 0–1 days after birth, triangles display children
randomised 2–7 days after birth. Error bars depict 95% CI.
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Fig. 3. Geometric mean ratios (GMRs) of effect of BCG on antibodies against
pneumococcal capsular polysaccharide antigens (anti-Pn Ps IgG) for each pneumo-
coccal serotype. Dots display all children, squares display children randomised 0–
1 days after birth, triangles display children randomised 2–7 days after birth. Error
bars depict 95% CI.
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4.2. Comparison with other studies
In The Gambia, Ota et al. measured antibodies at 4.5 months of
age after receiving diphtheria-tetanus-pertussis (DTP) vaccine at 2,
3 and 4 months. They found no effect of BCG at birth on anti-TT nor
anti-PT comparing children BCG vaccinated at birth with children
not yet BCG vaccinated at the time of bleeding, but BCG-at-birth
was associated with higher antibody response to Hepatitis B vacci-
nation at birth, 2 and 4 months of age. They also studied the effect
of BCG at 2 months of age, comparing again with children not yet
BCG vaccinated, and found that BCG at 2 months of age, but not
BCG at birth, was associated with higher antibody responses to oral
polio vaccine [16].
A more recent study from Australia measured vaccine
antibodies in 7-month-old children, 4 weeks after the last infant
vaccination. BCG-vaccinated children were recruited from a related
study randomising children with increased risk of TB to vaccina-
tion with BCG-Denmark, BCG-Japan or BCG-Russia [28]. Control
children were recruited at the vaccination clinic. BCG was given
at birth, and both the BCG group and the control group had
Infanrixhexa, Prevenar7 and RotaTeq at 2, 4 and 6 months. The
study found no effect of BCG on anti-TT and anti-Hib, but an inhi-
bitory effect on antibodies against Hepatitis B. In the BCG group,
children had higher antibody levels against S. pneumococcus
serotypes compared to the control group. The most significant
effect was seen for serotype 6B, 9V and 18C [19].
There are some significant differences between these two stud-
ies and the present study. All three studies have different vaccina-
tion programs in terms of vaccines and schedule. Also the times of
bleeding were different although both the Australian study and the
present study were measuring antibodies 4 weeks after the last
vaccine. We did not measure antibodies against Hepatitis B, as this
vaccine is not part of the standard vaccination programme in Den-
mark, but only offered to children of Hepatitis B-infected mothers
(only one child in this study).
Despite some important differences between the studies, our
observation that BCG may have an effect on the antibody response
against S. pneumococcal serotypes in children randomised at
day 2–7 supports previous findings of the Australian study on
the same serotypes [19]. This indicates that BCG may have NSEs
that increase antibody responses to routine vaccines, but the tim-
ing of BCG vaccination may be important. As a possible explanation
the development and changes in the neonatal immune system dur-
ing the first days of life could result in a varying response to BCG
vaccination [29–32].
The proportion of children with antibody levels above the limit
of protection was comparable with other studies for both BCG vac-
cinated and the control group [33–36]. Few children had antibody
levels below the limit of protection. Overall, antibody levels against
Hib and all Pneumococcus serotypes were lower among boys
compared to girls. Some studies have reported sex differences of
antibody levels against DT among adults [37], but we found no
differences for DT and TT. For PT on the other hand, boys in our
study tended to have a higher response compared to girls. Other
studies found higher antibody responses in females than males
[38–42]. An explanation could be genetic differences as the
X-chromosome has several genes with potential influence on
immunocompetence [43].
The BCG effect in other studies has varied by sex [17,44,45], but
we observe no such differences by sex. Maternal BCG status did not
modify the effect of BCG in the present study, although we have
found that maternal BCG may influence the effect of neonatal
BCG in regard to the risk of hospitalisation for infection (in
submission).
Antibody response to routine vaccinations in our population
was almost complete since nearly all children had protective
levels. However, this absence of effect of BCG in a setting of good
vaccine responsiveness should not detract from future studies in
which BCG should be tested in situations in which basal vaccine
responses are poorer: such examples can be vaccination with less
effective vaccines, or in individuals with poor reactivity. In line
with this, a recent randomised trial in adults showed improved
antibody titres and seroconversion from 60% to 80% against
H1N1 influenza by BCG [46], while in the present study all sero-
conversions were above 96% even in the absence of BCG.
5. Conclusion
In conclusion, we did not find an overall effect of BCG vaccina-
tion on antibody levels after pentavalent vaccines given during the
first year of life. Age at BCG vaccination may be a modifying factor,
as BCG vaccination 2–7 days after birth might have an enhancing
effect on antibody responses. This would be important to assess
in future studies of possible non-specific effects of BCG on antibody
responses. This study adds to a growing number of studies showing
that girls mount higher antibody responses than boys.
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